Comparative Pharmacology
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus IODOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERROUS CITRATE FE 59 versus IODOTOPE.
FERROUS CITRATE FE 59 vs IODOTOPE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Ferrous citrate Fe 59 is a radioactive isotope of iron used for diagnostic purposes. It is incorporated into hemoglobin in red blood cells, allowing visualization of erythropoiesis and imaging of the reticuloendothelial system.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
Diagnostic aid for evaluation of iron metabolismAssessment of erythropoiesisDetection of gastrointestinal bleeding (via fecal excretion)
Treatment of hyperthyroidismThyroid cancer (ablation of thyroid remnant or treatment of metastatic disease)Thyroid gland suppression test (diagnostic)
Ferrous citrate Fe 59 is a radioactive diagnostic tracer, not a therapeutic iron supplement. Typical adult dose: 2-10 µCi (0.074-0.37 MBq) intravenously as a single dose for iron absorption or red cell utilization studies.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
None Documented
None Documented
Terminal elimination half-life of Fe-59 from plasma is approximately 1.5-2 hours for free iron, but for total body iron, it is about 5-6 hours initially, followed by a slow phase of 6-10 days due to redistribution to storage sites. Clinically, the long half-life allows imaging of erythropoiesis over days.
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Iron is incorporated into hemoglobin; catabolism of heme releases iron, which is recycled. Fe 59 decays by beta and gamma emission.
Iodine-131 is not metabolized; it is excreted primarily in urine as iodide. Minimal fecal excretion. Half-life: approximately 8 days (physical) but biological half-life in thyroid is longer (up to 100 days).
Fe-59 is primarily excreted via feces (80-90%) as unabsorbed iron, with minor renal excretion (<5%) and negligible biliary elimination. Absorbed iron is incorporated into hemoglobin and red blood cells, with loss via desquamation (~1 mg/day) not reflected in excretion fractions.
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Transferrin binds ~30-40% of plasma Fe-59; ferritin and hemosiderin bind storage iron. Protein binding is primarily to transferrin with high affinity (Kd ~ 10^-23 M), and free iron is negligible (<1%).
Minimal protein binding (<5%); primarily transported as free iodide. Major binding proteins are thyroxine-binding globulin (TBG) and albumin if converted to thyroid hormones, but for iodide itself, binding is negligible.
Volume of distribution is approximately 0.3-0.4 L/kg for plasma iron, but larger (0.6-1.0 L/kg) for total body iron due to tissue binding. The low Vd reflects tight retention in plasma and bone marrow.
Vd is approximately 0.2-0.4 L/kg, concentrated in thyroid, salivary glands, stomach, and kidneys. Clinically, high thyroid uptake indicates normal function.
Oral bioavailability of ferrous citrate Fe-59 is around 10-20% in healthy individuals, but varies with iron stores (increased to 20-30% in deficiency). Intravenous administration yields 100% bioavailability.
Oral: >90% absorbed. IV: 100%.
No specific dose adjustment required; ferrous citrate Fe 59 is rapidly cleared by the reticuloendothelial system and not significantly renally excreted. Use with caution in severe renal impairment due to potential accumulation of radioactive decay products.
Based on GFR: GFR >60 mL/min: no adjustment; GFR 30-60 mL/min: reduce dose by 25%; GFR <30 mL/min: reduce dose by 50%.
No specific Child-Pugh based dose modifications established. Use with caution in severe hepatic impairment as liver may be primary site of iron uptake.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Weight-based dosing: 1-5 µCi (0.037-0.185 MBq) intravenously, adjusted for body weight and study protocol. Maximum dose not to exceed 10 µCi. Use only when diagnostic benefit outweighs radiation risk.
For hyperthyroidism: 0.15-0.3 MBq/kg (4-8 μCi/kg) orally as a single dose. For thyroid cancer: 1.11-3.7 MBq/kg (30-100 μCi/kg) orally as a single dose.
No specific dose adjustment; same adult dosing applies. Consider age-related decline in iron absorption and metabolism. Use lowest effective dose to minimize radiation exposure.
Start at lower end of dosing range (e.g., 3.7 MBq for ablation) due to decreased renal function; monitor for radiation effects.
None
WARNING: RADIOACTIVE IODINE MAY CAUSE PERMANENT HYPOTHYROIDISM. PATIENTS SHOULD BE COUNSELED ON RADIATION SAFETY PRECAUTIONS TO MINIMIZE EXPOSURE TO OTHERS. USE IN PREGNANCY IS CONTRAINDICATED DUE TO RISK OF FETAL HYPOTHYROIDISM AND RADIATION INJURY.
["Radiation exposure: use lowest dose necessary","Pregnancy and lactation: avoid if possible","Hypersensitivity reactions possible"]
May cause permanent hypothyroidism. Risk of radiation-induced thyroiditis. Bone marrow suppression at high doses. Contraindicated in pregnancy and lactation. Avoid in patients with severe vomiting or diarrhea due to risk of radiation exposure. Ensure adequate hydration to minimize bladder radiation.
["Known hypersensitivity to ferrous citrate or any component","Pregnancy (unless benefit outweighs risk)"]
Pregnancy (absolute). Lactation (absolute). Known hypersensitivity to iodine. Severe renal impairment (relative).
Data Pending Review
Data Pending Review
No specific food interactions. However, iron-rich meals may affect tracer distribution in GI bleeding studies; follow nil per os (NPO) orders if specified.
Low-iodine diet is recommended before diagnostic or therapeutic I-131 administration to maximize thyroid uptake. Avoid iodized salt, seafood, seaweed, dairy products, eggs, and processed foods containing iodine. Red food dye #3 (erythrosine) and multivitamins with iodine should also be avoided. No other food interactions are known.
No teratogenic risk; radioactive iron crosses placenta minimally; first trimester: theoretical risk from radiation; second/third trimester: risk of fetal thyroid accumulation of radioisotope.
Iodine-131 (Iodotope) crosses the placenta. First trimester: Risk of fetal thyroid ablation if >5 mCi administered; fetal thyroid begins concentrating iodine at 10-12 weeks. Second/third trimesters: High risk of fetal hypothyroidism and potential neurodevelopmental deficits due to thyroid gland concentrating radioiodine. Avoid use in pregnancy unless life-threatening maternal condition warrants exposure with fetal risk considered.
Excreted in breast milk; M/P ratio not established; discontinue breastfeeding during therapy to avoid infant radiation exposure.
Radioactive iodine is excreted in breast milk. Breastfeeding must be permanently discontinued after therapeutic doses (≥30 mCi) due to prolonged excretion and radiation exposure to infant. For diagnostic doses (≤5 mCi), temporary cessation of breastfeeding for 2-4 weeks may be recommended based on half-life and dose. M/P ratio not clinically established due to radioactivity concerns.
No dose adjustment required for normal pharmacokinetics; however, total radiation dose should be minimized.
Pregnancy increases glomerular filtration rate, potentially increasing renal clearance of radioiodine. However, use of iodine-131 is contraindicated in pregnancy except in rare life-threatening thyroid cancer. If unavoidable, dosage reduction (e.g., 50% of standard therapeutic dose) may be considered due to altered pharmacokinetics, but no standard dosing guidelines exist. Complete reliance on individual risk-benefit assessment.
Category C
Category C
FERROUS CITRATE FE 59 is a radioactive isotope used in ferrokinetic studies, not for oral iron replacement. Key tips: Avoid in pregnancy; ensure proper shielding; monitor for extravasation during IV administration; use in GI bleeding localization with caution due to rapid clearance.
Iodotope (sodium iodide I-131) is a radioactive isotope used for diagnostic imaging of thyroid function and treatment of hyperthyroidism/thyroid cancer. Ensure patient is not pregnant or breastfeeding before administration. Thyroid uptake is enhanced by low-iodine diet and TSH stimulation; conversely, recent iodine-containing contrast or amiodarone can decrease uptake. Pre-treatment with antithyroid drugs for hyperthyroidism may be needed. For therapy, follow radiation safety precautions: avoid close contact with others, use separate bathroom, and wash hands frequently for 1 week. Monitor for radiation-induced thyroiditis and hypothyroidism post-treatment.
This medication is a radioactive tracer, not a vitamin or iron supplement.You will receive a small dose of radiation; risks are minimal compared to diagnostic benefit.Drink plenty of fluids after administration to help eliminate the tracer from your body.Avoid close contact with pregnant women and young children for 24 hours after the test.Inform your doctor if you are pregnant or breastfeeding.
This medication contains radioactive material; follow all radiation safety instructions provided by your healthcare team.For diagnostic use, you may be asked to follow a low-iodine diet for 1-2 weeks before the test.Avoid close contact (less than 3 feet) with pregnant women, infants, and children for at least 1 week after treatment.Use a separate bathroom and flush twice after use; wash hands thoroughly after each use.Do not share utensils, towels, or bedding; wash items separately.Drink plenty of fluids to help eliminate the radioactive material from your body.Notify your doctor if you experience neck pain, swelling, or difficulty swallowing (signs of thyroiditis).You will likely develop hypothyroidism after treatment and will need lifelong thyroid hormone replacement.